Business Context and Reporting Period
Company: Akers Biosciences, Inc. (Ticker: AKER)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2020
Reporting Period: Event date May 14, 2020; Expected closing on or about May 18, 2020.
The Company entered into a Securities Purchase Agreement to conduct a registered direct offering of common stock.
Key Financial Metrics
| Metric | Value |
|---|---|
| Shares Issued | 1,366,856 |
| Offering Price per Share | $3.53 |
| Gross Proceeds | Approximately $4.825 million |
| Placement Agent Fees | 7.5% cash fee + 1.0% management fee of gross proceeds |
| Placement Agent Warrants | 109,348 shares at $4.4125 exercise price (5-year term) |
| Other Expenses | $50,000 (non-accountable) + $12,900 (clearing) |
| Estimated Net Proceeds | Approximately $4.3 million |
Note: This filing does not provide revenue, profit, cash flow, margins, or debt figures for the Company's operations.
Material Changes
This filing reports a material definitive agreement regarding a capital raise. There are no comparative financial metrics provided in this document to assess changes in operating performance versus prior periods.
Outlook, Risks, and Management Commentary
- Transaction Status: Closing is subject to customary conditions and is expected on or about May 18, 2020.
- Use of Proceeds: The filing does not specify the intended use of the net proceeds.
- Risk Disclosures: The Company notes that representations and warranties in the Purchase Agreement are for risk allocation between parties and may not reflect materiality standards for stockholders. Information regarding these representations may change after the agreement date.
- Unregistered Securities: Placement Agent Warrants are issued under Section 4(a)(2) and Regulation D exemptions and are not registered under the Securities Act.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected May 18, 2020).
- Confirm the final net proceeds after all fees and expenses are deducted.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Check subsequent filings for the Company's stated use of the raised capital.
- Monitor the impact of the 1,366,856 new shares on existing shareholder dilution.